Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.

@article{Giovannetti2017RoleOP,
  title={Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.},
  author={Elisa Giovannetti and Paolo Andrea Zucali and Yehuda G Assaraf and Niccola Funel and Maria Grazia Gemelli and Michal J Stark and Erik B Thunnissen and Zhanjun Hou and Ittai B Muller and Eduard Alexander Struys and Matteo Perrino and Gerrit Jansen and Larry H. Matherly and Godefridus J. Peters},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2017},
  volume={28 11},
  pages={
          2725-2732
        }
}
Background Thymidylate synthase (TS) has a predictive role in pemetrexed treatment of mesothelioma; however, additional chemoresistance mechanisms are poorly understood. Here, we explored the role of the reduced-folate carrier (RFC/SLC19A1) and proton-coupled folate transporter (PCFT/SLC46A1) in antifolate resistance in mesothelioma. Patients and methods PCFT, RFC and TS RNA and PCFT protein levels were determined by quantitative RT-PCR of frozen tissues and immunohistochemistry of tissue… CONTINUE READING